Global Point of Care

Results on your schedule. Answers in your hands.

Respiratory infections are contagious, so quick results are important.

Easier access. Faster results. That’s the power of rapid testing.

There’s rarely a convenient time to take a medical test. The good news is, you no longer need to go out of your way to get fast, simple, and more accessible testing. From corner pharmacies to local urgent care clinics, our rapid test products are widely available. They’re essential tools in helping to reduce the spread because they quickly identify respiratory infections.

Available Products
ID NOW

ID NOW™ Rapid Molecular Testing

Used widely by urgent care clinics and pharmacies, ID NOW is fast, convenient, and proven way to test for respiratory infections. Available tests:

  • Influenza (Flu)
  • Strep A
  • COVID-19
  • RSV
BinaxNOW COVID-19 Antigen Self-Test

BinaxNOW COVID-19 Antigen Self Test

A simple solution for COVID-19 infection detection, with rapid results in the convenience of your home. Find it over the counter at your local pharmacy or retailer. Detects multiple strains, including Delta Variant.*

Find Tests Near You

This search tool will help you find the test you need at the location you prefer. To get started, find a healthcare provider offering ID NOW rapid molecular testing or a location where BinaxNOW COVID-19 Antigen Self Test is available.

Healthcare Professionals

To be added to our ID NOW Healthcare Professional locator tool, please provide the required information for each location you would like to be included on the locator tool.

*Abbott conducted a computational analysis of the detection of multiple SARS-COV-2 Strains, including the Delta variant, and predicts no impact to the performance of our BinaxNOW™ COVID-19 Antigen Self Test.

The BinaxNOW™ COVID-19 Antigen Self Test has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization. It has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb 3(b)(1), unless the declaration is terminated or authorization is revoked soon. The BinaxNOW COVID-19 Antigen Self-Test should be performed twice in 3 days, at least 36 hours apart.

The ID NOW C™OVID-19 EUA has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization for use by authorized laboratories and patient care settings. The test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

   

False
accessibility

   

YesNo
accessibility

   

YesNo